Olema Oncology's Upcoming Conference Presentation
Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", NASDAQ: OLMA) is poised to make a significant impression at the upcoming TD Cowen 45th Annual Health Care Conference. On Wednesday, March 5, 2025, at 10:30 a.m. ET, President and CEO, Sean P. Bohen, M.D., Ph.D., will be delivering a presentation that promises to highlight the innovative approaches Olema is taking in the realm of breast cancer treatment.
Live Webcast Information
For those interested in attending virtually, a live webcast of the presentation will be accessible under the Events and Presentations section of Olema's Investor Relations website. This is an exciting opportunity for stakeholders and interested parties to gain insights into Olema's latest advancements and future endeavors. Following the event, a recording of the presentation will be made available for those unable to attend live.
Understanding Olema Oncology
Olema Oncology is dedicated to transforming the standard of care in breast cancer treatment. The clinical-stage biopharmaceutical company is focused on discovering, developing, and commercializing targeted therapies that aim to improve outcomes for patients affected by this prevalent disease. Their novel therapies are rooted in a comprehensive understanding of endocrine-driven cancers, nuclear receptors, and the mechanisms underlying acquired resistance.
Innovative Product Pipeline
At the forefront of Olema's pipeline is palazestrant (OP-1250), an innovative product candidate that functions as a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). Currently, palazestrant is undergoing a Phase 3 clinical trial known as OPERA-01, which aims to evaluate its effectiveness in treating breast cancer. In addition to this, Olema is actively working on the development of OP-3136, a potent KAT6 inhibitor that is designed to address additional cancer treatment needs.
Company Operations and Future Goals
Olema Oncology is headquartered in San Francisco and has expanded its operations to Cambridge, Massachusetts. With a commitment to patient care, Olema is working diligently to bring innovative therapies to market that will redefine treatment paradigms and improve patients' quality of life. Their focused approach on developing medications with a strong scientific foundation underscores their commitment to leading the charge in breast cancer treatment.
Engaging with Media and Investors
The leadership at Olema, particularly Courtney O'Konek, Vice President of Corporate Communications, plays a crucial role in maintaining open lines of communication with both media and investors. This interaction ensures that the latest developments and insights regarding the company’s initiatives are shared in a timely and efficient manner. Interested individuals can reach out to Courtney via the provided contact information to explore more about Olema's valuable work.
Frequently Asked Questions
What is the focus of Olema Oncology?
Olema Oncology focuses on developing targeted therapies for breast cancer and other endocrine-driven cancers.
Who is presenting at the TD Cowen conference?
Sean P. Bohen, M.D., Ph.D., the President and CEO of Olema, will be giving the presentation.
How can I watch the presentation live?
A live webcast of the presentation will be available on Olema's Investor Relations website.
What is the lead product candidate of Olema Oncology?
The lead product candidate is palazestrant (OP-1250), which is currently in Phase 3 clinical trials.
Where is Olema Oncology headquartered?
Olema Oncology is headquartered in San Francisco, California.
